Elkeles Tamar 4

What Happened

• Tamar Elkeles, a director of Glimpse Group, was awarded derivative equity (reported as option grants) in two separate grants: 37,500 shares on 2025-01-01 and 145,000 shares on 2026-05-01. Each grant is reported at $0.00 per share (i.e., an equity award/option grant, not an open-market purchase or sale). No cash value or exercise price is shown in the reporting; the filing does not reflect any sale or exercise.

Key Details

• Transaction types/dates: Award/Grant (code A) — 37,500 on 2025-01-01 ($0.00) and 145,000 on 2026-05-01 ($0.00).
• Total awarded: 182,500 shares (derivative securities/options).
• Vesting (from footnotes):
  • F1: The 37,500-option grant vests in equal monthly increments from 01/31/2025 through 12/31/2025.
  • F2: The 145,000-option grant vests 60,422 shares on 05/31/2026, then in equal monthly increments from 06/30/2026 through 12/31/2026.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing/Timeliness: The Form 4 was filed on 2026-06-18 and reports grants from 2025-01-01 and 2026-05-01; these grants were reported well after the usual 2-business-day window, so the filing is late.
• Other: Exhibit 24 (Power of Attorney) is listed in the filing remarks.

Context

• These are derivative option awards that vest over time — they do not represent an immediate open-market purchase or sale. Vesting is the schedule by which the director will become entitled to the underlying shares; exercising (and any exercise price or subsequent sale) would be reported separately if/when it occurs. Because the filing was submitted late, the market received the disclosure with delay; late filings do not change the factual nature of the grants but reduce the timeliness of the disclosure for investors.